Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Schizophrenia
In brief
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Key facts
- Study ID
- NCT07288333
- Run by
- Neurocrine Biosciences
- People needed
- 120
- Starts
- 2026-02-16
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurocrine Clinical Site — Kazanlak, Bulgaria (enrolling)
- Neurocrine Clinical Site — Pazardzhik, Bulgaria (enrolling)
- Neurocrine Clinical Site — Targovishte, Bulgaria (enrolling)
- Neurocrine Clinical Site — Târgu Mureş, Romania (enrolling)
- Neurocrine Clinical Site — London, United Kingdom (enrolling)
- Neurocrine Clinical Site — Oxford, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.